MeiraGTx (NASDAQ:MGTX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare MeiraGTx to related companies based on the strength of its analyst recommendations, earnings, profitability, dividends, valuation, risk and institutional ownership.
Institutional & Insider Ownership
67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares MeiraGTx and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MeiraGTx | $81.39 million | -$114.20 million | 10.58 |
| MeiraGTx Competitors | $688.58 million | $7.69 million | -18.30 |
Profitability
This table compares MeiraGTx and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MeiraGTx | 19.46% | 85.23% | 24.12% |
| MeiraGTx Competitors | -12,224.75% | -204.85% | -31.52% |
Risk and Volatility
MeiraGTx has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, MeiraGTx’s peers have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for MeiraGTx and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MeiraGTx | 0 | 3 | 5 | 0 | 2.62 |
| MeiraGTx Competitors | 9940 | 15326 | 45736 | 1606 | 2.54 |
MeiraGTx currently has a consensus target price of $24.00, suggesting a potential upside of 183.69%. As a group, “Biotechnology” companies have a potential upside of 133.42%. Given MeiraGTx’s stronger consensus rating and higher probable upside, equities analysts plainly believe MeiraGTx is more favorable than its peers.
Summary
MeiraGTx beats its peers on 8 of the 13 factors compared.
MeiraGTx Company Profile
MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
